Heartflow CFO Verghese sells over $1.2 million in company stock

Vikram Verghese, Chief Financial Officer at Heartflow Inc., executed two stock sales totaling $1.23 million in mid-September. The transactions, carried out under a predetermined trading plan enacted on June 4, 2026, occurred as the company's shares approached a 52-week peak of $52.22, following a significant 96% increase over six months.

Analyzed by InvestingPro, Heartflow's stock appears overvalued compared to its intrinsic value, placing it among firms on the most overvalued list. On September 17, Verghese sold 7,579 shares at prices between $50.00 and $50.29 per share, with a weighted average sale price of $50.1142. The next day, September 18, he sold an additional 16,766 shares at prices ranging from $50.00 to $52.11, with a weighted average sale price of $50.7531.

Post these sales, Verghese still retains 155,183 shares of Heartflow common stock. Recently, HeartFlow reported robust second-quarter 2026 earnings, surpassing revenue and earnings forecasts. The company generated $64.1 million in revenue, a 48% increase year-over-year, surpassing the projected $56.7 million and consensus estimates of $56.6 million.

HeartFlow also reported narrower-than-anticipated losses, posting an adjusted loss of negative $0.07 per share, outperforming Wall Street's estimate of a negative $0.19 per share. In response, Stifel raised its price target for HeartFlow shares to $45, maintaining a Buy rating, citing strong performance in HeartFlow’s plaque and FFRCT businesses as driving revenue growth.